

bempedoic acid / ezetimibe film-coated tablets (Nustendi®)

Daiichi Sankyo UK Limited

9 May 2025

ADVICE: in the absence of a submission from the holder of the marketing authorisation

bempedoic acid / ezetimibe (Nustendi®) is not recommended for use within NHSScotland.

Indication under review: in adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:

- in patients on a maximum tolerated dose of a statin and not adequately controlled with additional ezetimibe treatment or,
- in patients who are either statin-intolerant, or for whom a statin is contraindicated, and not adequately controlled with ezetimibe treatment or,
- in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

Bempedoic acid / ezetimibe (Nustendi®) has previously been accepted for restricted use in adults with primary hypercholesterolaemia or mixed dyslipidaemia ([SMC2406](#)). This advice remains valid.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair

Scottish Medicines Consortium

Published 09 June 2025